Supplementary



Figure S1 Bright-field images of cell proliferation in the (A) H1975 and PC9 zebrafish xenograft models, and (B) H1975-OR and PC9-OR zebrafish xenograft models (scale bar, 500 μm). NC, negative control; Osi, osimertinib; Anl, anlotinib; Osi + Anl, osimertinib combined with anlotinib

https://dx.doi.org/10.21037/tlcr-24-759



Figure S2 Bright-field images of cell migration in the (A) H1975 and PC9 zebrafish xenograft models, and (B) H1975-OR and PC9-OR zebrafish xenograft models (scale bar, 200 μm). NC, negative control; Osi, osimertinib; Anl, anlotinib; Osi + Anl, osimertinib combined with anlotinib.

https://dx.doi.org/10.21037/tlcr-24-759



Figure S3 A statistical graph showing the results of cell proliferation in a zPDX model derived from patients. *, P<0.05; **, P<0.01; ***, P<0.001; NS, not significant. Each data point represents an independent biological replicate. NC, negative control; Osi, osimertinib; Anl, anlotinib; Osi + Anl, osimertinib combined with anlotinib.

https://dx.doi.org/10.21037/tlcr-24-759



Figure S4 Bright-field images of cell proliferation in a zPDX model derived from patients with NSCLC who are clinically sensitive to osimertinib (scale bar, 500 μm). NC, negative control; Osi, osimertinib; Anl, anlotinib; Osi + Anl, osimertinib combined with anlotinib; zPDX, zebrafish patient-derived xenograft.

https://dx.doi.org/10.21037/tlcr-24-759



Figure S5 Bright-field images of cell proliferation in a zPDX model derived from patients with NSCLC who are clinically resistant to osimertinib (scale bar, 500 μm). NC, negative control; Osi, osimertinib; Anl, anlotinib; Osi + Anl, osimertinib combined with anlotinib; zPDX, zebrafish patient-derived xenograft.

https://dx.doi.org/10.21037/tlcr-24-759